Research and Clinical Trials

Title  
Optimum/AC-058B301
Brief Description  
Subjects 18 to 55 years of age will be randomly assigned to take ponesimod or teriflunomide (Aubagio) pills daily; they have an equal chance of getting either treatment. The treatment will last for 108 weeks. An end-of-treatment visit will take place at Week 108. All subjects will enter the safety follow-up period (2 to 4 weeks). For an individual subject, the maximum duration of the study will be approximately 118 weeks (2.2 years).
Who may be Eligible  
People 18-55 years of age with relapsing forms of multiple sclerosis
Start Date  
08/05/2015
IRB Number  
08-15-09A
Principal Investigator  
Conway, Jill
Contact Name  
Maryanne

For More Information, Contact   Maryanne  Burdette , RN
Phone:  (704) 446-1925  Fax:  (704) 446-0840 
Email:  Maryanne.burdette@carolnashealthcare.org
Address:  Neurosciences Institute: Neurology-Charlotte
Close